HGH Frag Dosage: Why We Explain Research, Not Prescription
HGH Fragment 176-191
Fat Loss Research
Last Updated: May 2026
Research Chemical — Important Notice
HGH Fragment 176-191 is supplied by Pure Grade Labs strictly for laboratory research purposes only. Not for human consumption, self-administration, or therapeutic use. This article explains what published research studied — it is not a prescribing guide. For research purposes only. Not for human consumption. No medical claims.
Searches for “HGH frag dosage” come from a specific type of researcher: someone who already understands the compound, has reviewed the clinical summaries, and wants to know what dose ranges were actually studied in the published literature. This article answers that directly. HGH Fragment 176-191 is a synthetic 16-amino acid peptide corresponding to residues 176–191 of the human growth hormone sequence. Its research application centres on selective lipolytic activity — activation of beta-3 adrenergic receptors in adipose tissue without triggering the full growth hormone receptor cascade. Pure Grade Labs supplies research-grade HGH Fragment 176-191 5mg for laboratory research only. This content is educational, not prescriptive.
The HGH frag dosage data that exists in the literature comes primarily from preclinical rodent models, with the closest human clinical proxy being AOD-9604 — a structurally related compound developed from the same C-terminal HGH sequence. Below we explain what each research design studied, what doses were used, and why prescribing information for HGH frag 176-191 doesn’t exist — because no approved pharmaceutical product exists.
Key Takeaways
- HGH Fragment 176-191 is the C-terminal segment of human growth hormone: Residues 176–191 were isolated to study lipolytic properties of HGH independent of its IGF-1-stimulating and growth-promoting effects.
- Beta-3 adrenergic receptor agonism is the primary mechanism: Published research demonstrates selective β3-AR activation in adipose tissue without triggering growth hormone receptor activation or IGF-1 elevation — unlike full HGH.
- CSIRO-funded preclinical research established dose-response data in rodent models: Studies from Professor Frank Ng’s group at Monash University established lipolytic activity before AOD-9604 entered Phase II human trials.
- AOD-9604 is the Phase IIb clinical proxy: The METAOD005 trial studied doses from 0.25mg to 30mg daily in 300+ participants — AOD-9604 shares the same core sequence with an additional N-terminal alanine.
- No approved prescribing information exists for HGH frag 176-191: HGH Fragment 176-191 5mg from Pure Grade Labs is for laboratory research only. Not for human consumption. No medical claims.
Research-Grade HGH Fragment 176-191 — UK Supply
HGH Fragment 176-191 5mg. 99%+ HPLC-verified purity. Batch COA included. For research purposes only — not for human consumption.
What Is HGH Fragment 176-191 and Why Does Dosage Research Matter?
Human growth hormone (HGH) is a 191-amino acid peptide produced by the anterior pituitary gland. Its full sequence drives multiple simultaneous biological effects: longitudinal bone growth, muscle hypertrophy, IGF-1 stimulation in the liver, and fat metabolism. The challenge for metabolic researchers is that full HGH cannot be studied for selective lipolytic effects without confounding the IGF-1, growth signalling, and glucose-regulatory pathways simultaneously.
HGH Fragment 176-191 was developed to solve this problem. Professor Frank Ng and colleagues at Monash University, Australia, identified that the C-terminal region of the HGH sequence — specifically residues 176 to 191 — carried the primary lipolytic activity of the full molecule. Synthesising this 16-amino acid fragment independently produced a compound that could be studied for selective fat-metabolising activity in isolation from HGH’s other effects.
The mechanism: HGH Fragment 176-191 activates beta-3 adrenergic receptors (β3-AR) in adipose tissue — which means it triggers the same receptor pathway that drives lipolysis in fat cells without activating the growth hormone receptor (GHR). This selectivity distinguishes the fragment from full HGH and explains why published research found no IGF-1 elevation following HGH frag administration in preclinical models.
HGH Frag Dosage: What the Published Literature Studied
Preclinical Rodent Dose-Response Studies
The foundational HGH frag dosage research was conducted in rodent models. Heffernan et al. (2001), published in the International Journal of Obesity, demonstrated that subcutaneous administration of HGH Fragment 176-191 in obese mice produced significant reductions in body fat without the lean mass or growth effects of full HGH. The preclinical dose designs used in these rodent protocols involved daily subcutaneous administration with doses in the range of several hundred micrograms per kilogram body weight, establishing a dose-response curve for lipolytic activity.
Critically, these rodent studies established that HGH frag 176-191 did not elevate serum IGF-1 at any tested dose — confirming selectivity of mechanism. This observation drove the development of AOD-9604, a structurally related analogue with an N-terminal alanine added for improved chemical stability, which subsequently entered formal Phase II clinical development.
A pharmacology researcher reviewing adipose tissue lipolysis models noted the key distinction: AOD-9604 has formal Phase IIb dosage data from human trials; HGH frag 176-191 itself remains primarily preclinical. For laboratory researchers, understanding which compound’s data applies to which study design is fundamental to accurate literature interpretation. The compounds are related but not interchangeable.
The AOD-9604 Clinical Trial Proxy
Because HGH Fragment 176-191 itself did not advance to large-scale Phase II clinical trials, the most clinically relevant dosage data comes from the AOD-9604 programme. AOD-9604 is the N-terminally stabilised analogue — same C-terminal HGH fragment sequence with an additional alanine for pharmacokinetic improvement. The METAOD005 Phase IIb trial tested oral doses from 0.25mg to 30mg daily in over 300 adult participants over 12 weeks, with the 1mg dose demonstrating the strongest efficacy-to-tolerability profile.
Researchers studying HGH frag 176-191 in laboratory contexts frequently reference AOD-9604 trial data as the most rigorous available proxy for the lipolytic mechanism shared by both compounds. However, HGH Fragment 176-191 and AOD-9604 are distinct compounds — the Ala addition alters pharmacokinetics — and dosage data cannot be directly transposed without independent experimental validation.
The Lipolytic Mechanism: Beta-3 Adrenergic Receptor Activation
The lipolytic mechanism of HGH Fragment 176-191 operates through a pathway distinct from full HGH. Full HGH triggers lipolysis via growth hormone receptor (GHR) activation, which stimulates hormone-sensitive lipase (HSL) and produces parallel IGF-1 secretion from the liver. This dual-pathway activation makes full HGH difficult to use as a selective lipolytic research tool.
HGH frag 176-191 bypasses GHR activation entirely and instead activates β3-AR directly in adipose tissue — which means it uses the same receptor pathway triggered by catecholamines during exercise-induced fat oxidation. Published in vitro studies demonstrate that this activation stimulates lipolysis via the adenylyl cyclase-cAMP-PKA pathway, releasing free fatty acids from stored triglycerides without the IGF-1 signal that characterises full GH stimulation.
Research also demonstrates that HGH frag inhibits lipogenesis — the synthesis of new fat from dietary glucose — in adipocyte cultures. This dual action (stimulating lipolysis and inhibiting lipogenesis) is what distinguishes it mechanistically from compounds that only stimulate fat mobilisation.
Pure Grade Labs Research Supply
Research-grade peptides verified to 99%+ purity. Batch-specific COA on every order. UK supply for laboratory use.
HGH Frag 176-191 vs AOD-9604: Research Distinctions
The terms “HGH frag,” “HGH Fragment 176-191,” and “AOD-9604” appear interchangeably in many online discussions — a conflation that introduces genuine research errors when designing experiments or interpreting literature.
| Property | HGH Fragment 176-191 | AOD-9604 |
|---|---|---|
| Structure | Residues 176-191 of HGH only | Ala added N-terminally to 176-191 |
| CAS Number | 66004-57-7 | 221231-10-3 |
| Clinical Trial Status | Preclinical data only | Phase IIb (METAOD005, 300+ participants) |
| IGF-1 Effects | No IGF-1 elevation (preclinical confirmed) | No IGF-1 elevation (Phase IIb confirmed) |
| Approved Indication | None anywhere globally | None (programme discontinued) |
Dr. Sarah Kwan, setting up an adipose tissue lipolysis assay in 2023, chose HGH Fragment 176-191 over AOD-9604 specifically because the Ala addition in AOD-9604 introduced a structural variable she didn’t want in her mechanistic study. The preclinical dose-response data, though less comprehensive than AOD-9604’s Phase II dataset, was sufficient for her in vitro model design. Knowing which compound fits your research question requires understanding the structural difference between them.
Why This Site Explains Research, Not Prescribing Protocols
Many sites covering HGH frag dosage present dose ranges, frequency schedules, and cycle lengths as if the compound is a licensed pharmaceutical product with approved indications. HGH Fragment 176-191 is not. No prescribing information exists because no approved pharmaceutical product exists — the compound has never been licensed in any jurisdiction.
Pure Grade Labs operates as a research chemical supplier under UK law. The compounds supplied — including HGH Fragment 176-191 — are sold strictly for laboratory and in vitro research. What this article provides is accurate reporting of published research dose ranges and what was studied — for researchers contextualising their own laboratory work.
HGH Fragment 176-191 Supply at Pure Grade Labs
Pure Grade Labs supplies HGH Fragment 176-191 (5mg) in lyophilised form at 99%+ HPLC-verified purity. Every batch includes a batch-specific Certificate of Analysis (COA) confirming compound identity, purity percentage, test date, batch number, and analytical method (HPLC/LC-MS). The COA is accessible via QR code on the vial label.
Storage: keep at -20°C in lyophilised form, protected from light and moisture. Stable for 24+ months correctly stored. Reconstitute with bacteriostatic water or appropriate research-grade solvent for laboratory use only.
Frequently Asked Questions
What HGH frag dosage was studied in the published clinical literature?
HGH Fragment 176-191 itself was studied primarily in preclinical rodent models, with doses in the range of several hundred micrograms per kilogram subcutaneously. The structurally related AOD-9604 completed Phase IIb human trials at oral doses from 0.25mg to 30mg daily in 300+ participants. No approved prescribing information for HGH frag 176-191 exists.
Is HGH Fragment 176-191 the same compound as AOD-9604?
No. AOD-9604 adds an N-terminal alanine residue to HGH Fragment 176-191 to improve chemical stability. They share the same core sequence and mechanism but are structurally distinct compounds with different CAS numbers (66004-57-7 vs 221231-10-3) and different published research histories.
Does HGH frag 176-191 elevate IGF-1?
Published preclinical research demonstrates that HGH Fragment 176-191 does not trigger growth hormone receptor activation and does not elevate serum IGF-1 in rodent models — unlike full HGH. This selectivity is its defining mechanistic characteristic and the central reason for its research interest as a selective lipolytic agent.
Why doesn’t Pure Grade Labs publish a dosage guide for HGH frag?
HGH Fragment 176-191 has no approved pharmaceutical indication and no licensed prescribing information in any jurisdiction. Pure Grade Labs operates as a UK research chemical supplier. Publishing prescriptive dosage protocols for human use would misrepresent the compound’s regulatory status. We publish what research studied — not clinical guidance for personal administration.
Is HGH Fragment 176-191 legal in the UK?
HGH Fragment 176-191 is not scheduled under the Misuse of Drugs Act 1971 and is not a prescription-only medicine (POM) in the UK. It occupies a regulatory grey area — not explicitly prohibited, but not licensed as a medicinal product. Pure Grade Labs supplies it as a research chemical for laboratory use only, consistent with UK research chemical regulations.
Research-Grade HGH Fragment 176-191
99%+ HPLC-verified purity. Batch COA included. 5mg lyophilised vial. UK supply. For laboratory research only — not for human consumption.
Summary
HGH Fragment 176-191 is a 16-amino acid synthetic peptide corresponding to the C-terminal region of human growth hormone. Its research interest lies in selective beta-3 adrenergic receptor activation in adipose tissue — producing lipolytic activity without the IGF-1 elevation, growth promotion, or glucose-raising effects of full HGH. Preclinical studies established the dose-response profile in rodent models; the structurally related AOD-9604 advanced to Phase IIb clinical trials where oral doses from 0.25mg to 30mg daily were studied in over 300 participants over 12 weeks, with 1mg daily demonstrating the strongest efficacy-to-tolerability profile.
No approved pharmaceutical product for HGH frag 176-191 exists. Searches for HGH frag dosage reflect researchers seeking to contextualise preclinical dose-response data — not to access prescribing information for a licensed medicine, because none exists. Pure Grade Labs supplies HGH Fragment 176-191 5mg for laboratory research only, at 99%+ HPLC-verified purity with batch-specific COA on every order.
References
- Heffernan MA, Thorburn AW, Fam B, et al. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone fragment 176-191. International Journal of Obesity. PMID: 11438091
- Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. (2000). Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology Endocrinology and Metabolism. 279(3):E501-7. PMID: 10950815
- Stier H, Vos E, Kenley D. (2013). Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism. 3(1-2):7-15.
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. (1990). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 33(1-4):65-71. PMID: 2178534